This was my take from the announcement as well.

I think Don may have a diminished role going forward whether the trial succeeds or not.

Let the Goldman’s and Rothschilds of the world take the epigenetics story on to the Nasdaq.

Hopefully they take it forward with top line success (+CKD and cognition) but I think any of those being positive leads to a path forward for the company.

bfw